Adrenal collision tumors are rare clinical entities referring to separate coexisting adjacent tumors involving an adrenal gland with sharp demarcation between the two and without a substantial histologic admixture at the interface. We report a case of a 60-year-old female patient with an exceedingly rare adrenal hemangioma-adenoma collision tumor. To our knowledge, this is the first report of a collision tumor comprising an adrenal hemangioma and an adenoma.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmri.21430DOI Listing

Publication Analysis

Top Keywords

collision tumor
12
adrenal hemangioma-adenoma
8
exceedingly rare
8
rare adrenal
8
adrenal collision
8
adrenal
6
hemangioma-adenoma exceedingly
4
collision
4
tumor adrenal
4
collision tumors
4

Similar Publications

Biologic Downstaging Observed With a Pulmonary Collision Tumor.

Ann Thorac Surg Short Rep

September 2023

Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California.

Collision tumors are a rare entity in which 2 distinct neoplastic cellular populations invade each other and coalesce to form a single focal lesion. This case report describes a pulmonary collision tumor emerging from the rapid progression of 2 large-cell carcinoma lesions of the lung, including 1 nodule with clear cell features and another with basaloid features. The collision of these 2 histologically rare nodules resulted in the biologic downstaging of disease.

View Article and Find Full Text PDF

Background: Collision sellar tumors are rare disease entities. Less than 30 cases have been reported in the literature in the last 20 years. We present the case of one patient diagnosed with a collision sellar tumor and describe the use of Enhanced Contact Endoscopy for pituitary gland and tumoral identification not previously described in the literature.

View Article and Find Full Text PDF

The functionalization of protein sidechains with highly water-soluble chlorotriazines (or derivatives thereof) using nucleophilic aromatic substitution reactions has been commonly employed to install various functional groups, including poly(ethylene glycol) tags or fluorogenic labels. Here, a poorly soluble dichlorotriazine with an appended indole is shown to react with a construct containing the disordered domain of BRCA1. Subsequently, this construct can undergo proteolytic cleavage to remove the SUMO-tag: the -terminal poly(His) tag is still effective for purification.

View Article and Find Full Text PDF

Photoexcited Electro-Driven Reactive Oxygen Species Channeling for Precise Extraction of Biomarker Information from Tumor Interstitial Fluid.

Small

January 2025

Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, No. 174 Shazheng Road, Chongqing, 400044, China.

Direct electrochemical detection of miRNA biomarkers in tumor tissue interstitial fluid (TIF) holds great promise for adjuvant therapy for tumors in the perioperative period, yet is limited by background interference and weak signal. Herein, a wash-free and separation-free miRNA biosensor based on photoexcited electro-driven reactive oxygen channeling analysis (LEOCA) is developed to solve the high-fidelity detection in physiological samples. In the presence of miRNA, nanoacceptors (ultrasmall-size polydopamine, uPDA) are responsively assembled on the surface of nanodonors (zirconium metal-organic framework, ZrMOF) to form core-satellite aggregates.

View Article and Find Full Text PDF

Blunt abdominal trauma causing intraperitoneal injury and/or bleeding can be life-threatening, requiring immediate intervention. Diagnosing these cases can be challenging, especially when pre-existing conditions are involved. Low-grade appendiceal mucinous neoplasm (LAMN) is a rare tumor of the appendix that can lead to pseudomyxoma peritonei.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!